SUVEN.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 12:00):

Stats
Tagesvolumen	169 884
Durchschnittsvolumen	259 801
Marktkapitalisierung	24.30B
EPS	INR0 ( 2024-01-29 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-06
Last Dividend	INR1.382 ( 2019-02-14 )
Next Dividend	INR0 ( N/A )
P/E	-23.36
ATR14	INR0.209 (0.19%)

Volumen Korrelation

Lang: -0.18 (neutral)

Kurz: -0.57 (weak negative)

Signal:(59.706) Neutral

Suven Life Sciences Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Suven Life Sciences Korrelation - Währung/Rohstoff

0.56
( weak )

0.37
( neutral )

0.00
( neutral )

0.60
( weak )

0.06
( neutral )

-0.34
( neutral )

Suven Life Sciences Finanzdaten

Annual	2022
Umsatz:	INR135.39M
Bruttogewinn:	INR129.74M (95.82 %)
EPS:	INR-6.63

FY	2022
Umsatz:	INR135.39M
Bruttogewinn:	INR129.74M (95.82 %)
EPS:	INR-6.63

FY	2022
Umsatz:	INR118.44M
Bruttogewinn:	INR118.44M (100.00 %)
EPS:	INR-8.86

FY	2021
Umsatz:	INR134.78M
Bruttogewinn:	INR134.78M (100.00 %)
EPS:	INR-5.67

Financial Reports:

No articles found.

Suven Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Suven Life Sciences Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 1.881 - No dividend growth expected in the near future

Information

First Dividend	INR0.230	2004-09-10
Last Dividend	INR1.382	2019-02-14
Next Dividend	INR0	N/A
Payout Date	2019-02-25
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR8.02	--
Avg. Dividend % Per Year	0.00%	--
Score	0.66	--
Div. Sustainability Score	0
Div.Growth Potential Score	1.881
Div. Directional Score	0	--

Next Divdend (Est)
(2024-11-12)

INR0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.66

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.382	0.73%
2019	INR1.382	0.60%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TOUCHWOOD.NS	Dividend Junior	2023-09-22	Annually	6	0.15%
PGIL.NS	Dividend Junior	2023-09-01	Annually	17	1.08%
JINDALSAW.NS	Dividend Junior	2023-06-13	Annually	22	1.62%
DEEPAKNTR.NS	Dividend Junior	2023-07-27	Annually	14	0.25%
SKMEGGPROD.NS	Dividend Junior	2023-08-30	Sporadic	21	0.95%
MGEL.NS	Dividend Junior	2023-08-08	Annually	5	0.59%
HARSHA.NS	Dividend Junior	2023-09-20	Insufficient data to determine frequency	2	0.09%
BDL.NS	Dividend Junior	2023-09-20	Semi-Annually	7	1.17%
PTC.NS	Dividend Knight	2023-09-20	Annually	21	6.06%
KDDL.NS	Dividend Junior	2023-09-22	Annually	8	0.29%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-8.91	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.298	1.500	-4.42	-6.63	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-652.21	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.611	2.00	9.80	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.611	2.00	9.69	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	-1.686	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-9.99	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-4.38

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-22.89	1.000	-2.41	0	[1 - 100]
returnOnEquityTTM	-0.298	2.50	-2.84	-6.63	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.611	2.00	9.80	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.611	2.00	9.80	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.332	1.500	-1.121	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	1.119	1.000	10.00	0	[0.1 - 0.5]
Total Score				1.881

Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.